The mosquito transmitted Chikungunya virus, which causes Chikungunya fever, is spreading continuously. No vaccine is so far available. Researchers of the Paul-Ehrlich-Institut have experimentally recombined segments of the virus surface protein E2, thus creating artificial proteins. The domain generated that way -- "sAB+" -- was able to confer a protective effect against Chikungunya virus to the animal. An immunization by means of this small protein fragment could thus provide a suitable approach to developing a Chikungunya vaccine.
The Chikungunya virus (CHIKV) is transmitted by Aedes mosquitoes and causes an infection in humans known as Chikungunya fever. CHIKV occurs in the tropical and subtropical parts of the world. Regions where it has already caused epidemics include Africa, territories around the Indian Ocean, Southeast Asia, and meanwhile also the Caribbean, Central America, and South America. Around 1.2 million people are estimated to be infected so far during an epidemic in America. Since the Aedes albopictus mosquito, also known as Asian tiger mosquito, has now reached southern Europe and the USA, we are faced with further spreading of the virus. The Paul-Ehrlich-Institut has issued the regulation in 2007 that after returning from an endemic area, blood donors must be deferred from donating blood for at least two weeks to prevent an infection via the blood stream.
The disease is characterized by fever and severe joint pain, hence its name, which means "that which bends up." In 30 to 40 percent of the cases, these joint pains can last several months or even up to several years. Attempts at developing suitable vaccines have up to now been unsuccessful. To develop an effective vaccine, it is imperative to identify a suitable antigen structure of the virus which will create an effective immune response in humans. Previous approaches have used the entire E2 surface protein as a basis for the vaccine, partly in combination with other virus proteins. These proteins, however, have a relatively large structure, which would make commercial vaccine production difficult.
Professor Barbara Schnierle, head of the section "AIDS, New and Emerging Pathogens" of the division Virology at the Paul-Ehrlich-Institut and her team have investigated whether smaller more specific and less complex-to-be produced parts of E2 would suffice for conferring a protective immune response. Based on the three-dimensional structure of the protein, the researchers of the PEI selected different areas exposed on the surface to join them together, thus creating several artificial protein fragments. After production in E. coli and purification, mice were immunized with these protein fragments, and their blood was examined for neutralizing antibodies later on. In this experiment, one fragment, described as sAB+, proved to be the most effective one to induce neutralizing antibodies. It was used to immunize mice which were then infected by the wild-type Chikungunya virus. Compared with non-vaccinated animals, the mice treated showed significantly less virus RNA in the blood -- a sign of partial immune protection. "Our research work shows that single and artificially composed fragments of the Chikungunya virus surface protein may suffice to induce a partially protective immune response. "We consider our vaccine approach as promising for further development," said Professor Schnierle in her explanation of the research results.
Materials provided by PLOS. Note: Content may be edited for style and length.
Cite This Page: